Target : Multicenter, randomized and open trial evaluating the interest of a dose of prasugrel (Efient®) adapted to thebiological test VerifyNow (monitored arm) in comparison with a fixed dose of prasugrel (conventional arm) inpatients over 75 in need of angioplasty and stenting in order to reduce bleeding, ischemic complications as well as stent thrombosis.
Trial date : 2012
Number of patients : 877
Source of funding : Public (APHP) and private (Eli Lilly, Daiichi-Sankyo, Accriva diagnostics, Medtronic & Stentys)
Centers participating : 35 french centers
N°NCT : NCT01538446